Login

Apellis Pharmaceuticals, Inc. 4 SEC Filings

Filed On Filing
14 May 2026 Form 4: Dunlop A. Sinclair, Director

Disposed of 161,567 shares (Tender Offer) · Returned 20,311 shares to the issuer · Disposed of 102,826 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Chopas James George, VP/Chief Accounting Officer

Disposed of 65,955 shares (Tender Offer) · Received 38,244 shares as a grant or award · Returned 76,650 shares to the issuer · 1 more

14 May 2026 Form 4: Dolsten Mikael, Director

Disposed of 14,312 shares (Tender Offer) · Returned 14,312 shares to the issuer · Disposed of 24,135 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Meltzer Leslie, Chief Research and Development

Disposed of 107,024 shares (Tender Offer) · Received 67,830 shares as a grant or award · Returned 174,854 shares to the issuer · 1 more

14 May 2026 Form 4: Fonteyne Paul R., Director

Disposed of 30,666 shares (Tender Offer) · Returned 24,188 shares to the issuer · Disposed of 112,726 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Sullivan Timothy Eugene, Chief Financial Officer

Disposed of 212,437 shares (Tender Offer) · Received 159,080 shares as a grant or award · Returned 270,413 shares to the issuer · 1 more

14 May 2026 Form 4: Machiels Alec, Director

Disposed of 796,939 shares (Tender Offer) · Returned 20,311 shares to the issuer · Disposed of 242,300 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Deschatelets Pascal, Chief Scientific Officer

Disposed of 1,177,222 shares (Tender Offer) · Received 90,040 shares as a grant or award · Returned 135,445 shares to the issuer · 1 more

14 May 2026 Form 4: Chan Gerald, Director

Disposed of 25,666 shares (Tender Offer) · Returned 24,188 shares to the issuer · Disposed of 242,300 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Nicholson Nur, Chief Technical Officer

Disposed of 116,338 shares (Tender Offer) · Received 133,364 shares as a grant or award · Returned 221,303 shares to the issuer · 1 more

14 May 2026 Form 4: Walbert Keli, Director

Disposed of 17,051 shares (Tender Offer) · Returned 16,293 shares to the issuer · Disposed of 30,072 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: DeLong Mark Jeffrey, Chief Business & Strat Officer

Disposed of 114,591 shares (Tender Offer) · Received 115,165 shares as a grant or award · Returned 186,543 shares to the issuer · 1 more

14 May 2026 Form 4: O'Brien Stephanie Monaghan, Director

Disposed of 31,416 shares (Tender Offer) · Returned 24,188 shares to the issuer · Disposed of 242,300 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Boucher Kelley, Chief People Officer

Disposed of 127,804 shares (Tender Offer) · Received 45,219 shares as a grant or award · Returned 173,023 shares to the issuer · 1 more

14 May 2026 Form 4: Wheeler Craig A, Director

Disposed of 24,444 shares (Tender Offer) · Returned 23,071 shares to the issuer · Disposed of 42,879 Stock Option (right to buy) (Disposition to Issuer)

14 May 2026 Form 4: Watson David O., General Counsel

Disposed of 204,653 shares (Tender Offer) · Received 153,737 shares as a grant or award · Returned 267,033 shares to the issuer · 1 more

14 May 2026 Form 4: Francois Cedric, Director

Disposed of 1,805,259 shares (Tender Offer) · Received 524,786 shares as a grant or award · Returned 875,644 shares to the issuer · 1 more

14 May 2026 Form 4: Baumal Caroline, Chief Medical Officer

Disposed of 86,525 shares (Tender Offer) · Received 67,646 shares as a grant or award · Returned 118,953 shares to the issuer · 1 more

01 May 2026 Form 4: Baumal Caroline, Chief Medical Officer

Gave 900 shares as a gift

20 Apr 2026 Form 4: Sullivan Timothy Eugene, Chief Financial Officer

Gave 11,096 shares as a gift · Acquired 11,096 shares (Gift)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support